开盘$58.32
昨收$59.45
当日区间$58.22 – $59.61
成交量107.1K
市值$333.05B
市盈率（TTM）24.6
股息率2.61%
RHHBY 相关新闻
匹配 ROCHE HOLDING AG 或代码 RHHBY 的头条新闻，按最新排序。
- The Center for Drug Evaluation (CDE) has accepted Roche's (RHHBY.US) marketing application for faricimab injection, indicated for the treatment of uveitic macular edema.
- Roche (RHHBY.US) submits BTK inhibitor for market approval 正面
- Roche (RHHBY.US) reports positive mid-stage trial results for its weight-loss injection: average weight reduction of 15.5% over 48 weeks, with a 2.65% decrease in blood glucose indicators. 负面
- Morgan Stanley Upgrades ROCHE HOLDING AG(RHHBY.US) to Buy Rating, Raises Target Price to $507.41 正面
- From treatment to prevention! Roche (RHHBY.US) initiates clinical trial of Brainshuttle therapy for Alzheimer's disease
- Morgan Stanley Initiates ROCHE HOLDING AG(RHHBY.US) With Sell Rating, Announces Target Price $46
- Argus Research Initiates ROCHE HOLDING AG(RHHBY.US) With Buy Rating, Announces Target Price $55
- TD Cowen Maintains ROCHE HOLDING AG(RHHBY.US) With Hold Rating, Maintains Target Price $67
- TD Cowen Maintains ROCHE HOLDING AG(RHHBY.US) With Hold Rating, Raises Target Price to $67 正面
- Median survival extended by 5.7 months! Roche's (RHHBY.US) new lung cancer drug emerges victorious in head-to-head trial, providing a major catalyst for its oncology business.
- Barclays Initiates ROCHE HOLDING AG(RHHBY.US) With Buy Rating
- Goldman Sachs Initiates ROCHE HOLDING AG(RHHBY.US) With Hold Rating
- TD Cowen Maintains ROCHE HOLDING AG(RHHBY.US) With Hold Rating, Maintains Target Price $43
- Analysts Offer Insights on Healthcare Companies: SCHOTT Pharma AG & Co. KGaA (1SXP) and Roche Holding (RHHBY)
- HSBC Maintains ROCHE HOLDING AG(RHHBY.US) With Buy Rating, Raises Target Price to $57 正面
暂无评论——快来第一个聊聊 RHHBY。
登录后参与讨论。